Key facts
- This page summarizes Dror Bashan's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Aug 2023, 16:30.
Dror Bashan - 15 Aug 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- PLX
- Reported as of
- 15 Aug 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Aug 2023, 16:30:58 UTC
- Prior SEC filing
- 03 Apr 2024
- Next SEC filing
- 20 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eyal Rubin, POA
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dror Bashan filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 17 Aug 2023.
Change
- Previous filing in this sequence was filed on 03 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLX
transaction
Common Stock
Award
- Transaction value
- Shares
- +800,000
- Change %
- +74%
- Price
- Shares after
- 1,885,458
- Date
- 15 Aug 2023
- Ownership
- By Trust
- Footnotes
- F1, F2
PLX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 68,000
- Date
- 15 Aug 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. Of such shares, 200,000 shares were fully-vested upon grant and the remaining 600,000 shares vest over a two-year period beginning on the date of grant in eight equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
Footnote F2
To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.